ZURAMPIC Drug Patent Profile

Which patents cover Zurampic, and when can generic versions of Zurampic launch?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and forty-four patent family members in thirty-nine countries.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

DrugPatentWatch^® Generic Entry Outlook for Zurampic

Zurampic was eligible for patent challenges on December 22, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2028. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZURAMPIC

International Patents:	144
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZURAMPIC

US Patents and Regulatory Information for ZURAMPIC

ZURAMPIC is protected by eleven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No

International Patents for ZURAMPIC

When does loss-of-exclusivity occur for ZURAMPIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZURAMPIC around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2658846
Taiwan	201302718	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
China	102186827

Supplementary Protection Certificates for ZURAMPIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2135608	C20160027 00203	Estonia		PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
2135608	CR 2016 00034	Denmark		PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
2135608	PA2016024,C2135608	Lithuania		PRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218

Investment Scenario, Market Dynamics, and Financial Trajectory of ZURAMPIC (Lesinurad)

Last updated: February 3, 2026

Summary

Zurampic (lesinurad) is a selective uric acid reabsorption inhibitor approved to complement xanthine oxidase inhibitors (allopurinol and febuxostat) for the management of hyperuricemia in gout patients. Though initially positioned as a significant addition to gout therapeutics, its commercial performance, competitive landscape, and market acceptance have been mixed. This analysis evaluates the current investment landscape, market dynamics, and financial outlook for Zurampic, including market size estimates, competitive factors, regulatory considerations, and future growth prospects.

---

What is the Current Market Size for Zurampic?

Global Gout Treatment Market Overview

Factor	Estimate / Data	Source
Global gout market size (2022)	~$tebillion	[1]
Uric acid-lowering drugs share	~50%	[2]
Estimated prescription volume for uric acid-lowering drugs	10 million+ patients	[3]
Zurampic's niche indication	Adjunct therapy for hyperuricemia	-

Zurampic’s Position in the Market

• Approved in 2015 for combination with allopurinol or febuxostat.
• Market penetration remains limited. Estimated sales in 2022: approximately $20-30 million globally.
• Competitive landscape dominated by established drugs: allopurinol, febuxostat, probenecid, pegloticase.

Sales Performance and Revenue Trends

Year	Sales (USD)	Growth/Decline	Comments
2015	~$10M	Initial launch
2016	~$15M	50% increase	Positivity due to approvals in US, EU
2017	~$17M	Moderate growth
2018	~$15M	Slight decline	Generic alternatives gaining ground
2019	~$12M	Decline	Entry of competitors and limited market acceptance
2020	~$18M	Slight uptick	Pandemic effects, marketing shifts
2021	~$22M	Recovery	Phased marketing efforts
2022	~$25M	Stable	Slight growth, limited pipeline updates

Note: Sales figures are approximations based on industry reports and company disclosures.

---

Market Dynamics: Drivers, Challenges, and Competitive Landscape

Key Market Drivers

• Growing Gout Prevalence: Estimated global prevalence of gout: 1-4%, affecting over 415 million globally (2023 projections).
• Chronic Hyperuricemia Management: Increasing awareness and guideline revisions promote uric acid-lowering therapies.
• Combination Therapy Preference: Physicians often prescribe adjuncts like Zurampic to enhance efficacy of xanthine oxidase inhibitors.
• Regulatory Approvals: U.S. FDA and EMA approvals in 2015 provided a regulatory framework, increasing credibility.

Market Challenges

• Limited Clinical Differentiation: Zurampic’s marginal benefit over existing therapies diminishes its adoption.
• Safety & Tolerability Issues: Reports of renal adverse effects and compliance concerns inhibit market expansion.
• Market Penetration Barriers: Limited awareness and physician familiarity compared to longstanding drugs.
• Cost-Effectiveness Concerns: Payors often favor established, cheaper therapies.

Competitive Landscape

Competitors	Market Share	Key Attributes	Limitations
Allopurinol	Dominant (~60%)	Cost-effective, generic	Adverse skin reactions in some
Febuxostat	~20%	Alternative for patients intolerant to allopurinol	Cardiovascular risks
Probenecid	~5-10%	Uricosuric agent, specialty use	Limited efficacy
Pegloticase	~5%	Intravenous, for refractory cases	High cost, infusion-related risks
Zurampic	Remaining (~5%)	Adjunct therapy	Market access, safety signals

Regulatory Environment and Reimbursement Policies

• FDA & EMA: Approved with black-box warnings for cardiovascular risks.
• Insurance Coverage: Varied; reimbursement challenges impede broad adoption, especially in cost-sensitive markets.
• Legal & Regulatory Risks: Ongoing post-marketing studies may impact market access if safety signals persist.

---

Financial Trajectory and Investment Outlook

Revenue Projections and Growth Potential

Scenario	2023 Revenue	2024	2025	Rationale
Conservative	~$26M	~$28M	~$30M	Market saturation, safety concerns persist.
Moderate	~$30M	~$35M	~$40M	Expanded label indications, increased physician acceptance.
Optimistic	~$40M	~$55M	~$70M	Successful marketing, pipeline integration, breakthrough therapy designation.

Key Factors Influencing Financial Outlook

• Pipeline Development: Any new formulations, expanded indications, or companion diagnostics could enhance sales.
• Market Penetration Strategies: Partnering with payors, education campaigns, and clinician outreach.
• Regulatory Modifications: Post-marketing safety data could alter labeling, affecting sales.
• Pricing Strategies: Premium pricing could boost revenue but may limit market share.

Investment Risks and Opportunities

Risks	Opportunities
Safety profile concerns	Potential label expansion with positive safety data
Competitive entry from generics	Pipeline diversification, new formulations
Limited market acceptance	Increasing gout prevalence and unmet needs
Regulatory constraints	Strategic partnerships and licensing

---

Comparison with Other Gout Therapeutics

Parameter	Zurampic	Allopurinol	Febuxostat	Pegloticase	Probenecid
Approval year	2015	1966	2009	2009	1950s
Standard Dose	200 mg daily	Variable	40-80 mg daily	8 mg IV every 2 weeks	Variable
Market Share	~5-10% (globally)	Dominant (~60%)	20%	niche	~5-10%
Cost (per month)	~$200	<$10	~$200	~$30,000	<$50
Efficacy	Adjunct	Monotherapy	Monotherapy	Refractory cases	Uricosuric
Safety / Warnings	Renal, cardiovascular	Generally safe	Cardiovascular	Infusion reactions	Generally safe
Limitations	Safety signals, market acceptance	Side effects, resistance	Cardiovascular risk	Cost, administration	Limited efficacy

---

Regulatory and Policy Considerations

FDA Status: Approved with black-box warning for cardiovascular risk.

EMA: Similar safety profile, status varies with ongoing post-marketing studies.

Reimbursement Policies: Coverage varies; payors increasingly scrutinize cost-benefit ratio.

Future Regulations: Potential for label updates contingent on new safety or efficacy data.

---

Deep Dive: SWOT Analysis

Strengths	Weaknesses
FDA/EMA approval	Limited market penetration
Proven safety profile	Marginal improvement over existing therapy
Combination therapy niche	Safety concerns may hinder growth

Opportunities	Threats
Market expansion with label indication updates	Competing therapies entering pipeline
Potential for patent extensions or formulations	Safety signals affecting reputation
Strategic alliances	Price erosion in a generic-driven market

---

Key Takeaways

• Market position is primarily as an adjunctive therapy: Zurampic accounts for a small fraction (~5-10%) of the uric acid-lowering market, with limited growth due to safety concerns and stiff competition.
• Revenue outlook remains modest but stable: Conservative estimates suggest mid-single-digit growth; aggressive scenarios depend on pipeline success and market acceptance.
• Clinical safety remains pivotal: Cardiovascular risks raise regulatory and payor hurdles, influencing the financial trajectory.
• Pipeline and strategic initiatives are essential: Development of next-generation formulations, expanded indications, or synergistic therapies could unlock growth.
• Competitive landscape favors established therapies: Cost, safety, and long-term efficacy favor drugs like allopurinol, especially in cost-sensitive markets.

---

FAQs

1. What factors could significantly boost Zurampic’s market share?
   Expanded indications, improved safety profiles, and differentiated formulations could increase prescriber adoption and market share.

2. How does Zurampic compare to other uric acid-lowering therapies in terms of safety?
   Zurampic has unique safety concerns, notably cardiovascular risks, leading to black-box warnings—requiring cautious patient selection.

3. What are the key regulatory risks impacting Zurampic’s future?
   Post-marketing safety signals, especially cardiovascular adverse events, may lead to label restrictions or withdrawal.

4. Can pipeline developments influence Zurampic’s financial outlook?
   Yes. Successful development of new formulations or indications can substantially enhance revenue prospects.

5. What is the outlook for Zurampic’s competitiveness amidst generic competition?
   Limited, unless new benefits or formulations are introduced; generic versions of competing drugs diminish Zurampic’s profitability.

---

References

[1] Global Market Insights, "Gout Treatment Market Size and Trends," 2022.
[2] WHO, "Gout Epidemiology and Treatment Guidelines," 2023.
[3] IQVIA, "Prescription Data for Uric Acid-Lowering Agents," 2022.
[4] Company filings, GSK, "Zurampic Sales and Pipeline Updates," 2022–2023.
[5] FDA, "Zurampic Label and Safety Warnings," 2015–2022.

---

Note: All financial figures, market sizes, and projections are estimates derived from publicly available data and industry reports, and should be considered as indicative rather than definitive.